{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > IbrutinibCAS：936563-96-1
Molecular Formula：C25H24N6O2
Molecular Weight：440.5
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 936563-96-1 |
| Name | Ibrutinib |
| Molecular Formula | C25H24N6O2 |
| Molecular Weight | 440.5 |
| Solubility | Soluble in DMSO ≥5mg/mL |
| Purity | HPLC≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 805-642-2 |
| MDL | MFCD20261150 |
| SMILES | C=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O |
| InChIKey | XYFPWWZEPKGCCK-GOSISDBHSA-N |
| InChI | InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1 |
| PubChem CID | 24821094 |
| Target Point | Btk |
| Passage | Protein Tyrosine Kinase/RTK;Angiogenesis |
| Background | Ibrutinib is a small molecule BTK inhibitor that selectively covalently binds to the cysteine residue (Cys-481) on the active site of BTK, irreversibly inhibits the activity of BTK, thereby inhibiting BCR activation of signaling pathways. |
| Biological Activity | Ibrutinib (PCI-32765) 是选择性, 不可逆的 Btk 抑制剂, IC50 值为 0.5 nM。 |
| IC50 | IC50: 0.5nM (Btk) |
| Data Literature Source | [1]. Honigberg LA， et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20; 107 (29) :13075-80. [2]. Herman SE， et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9; 117 (23) :6287-96. [3]. Chang BY， et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13; 13 (4) :R115. [4]. Wu H， et al. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Sci Rep. 2017 Mar 28; 7 (1) :466. |
| Unit | Piece |
| Specification | 10mg 10mM*1mL in DMSO 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
